Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;161(4):444-446.
doi: 10.1001/jamadermatol.2024.6654.

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris

Billal Tedbirt  1   2 , Estelle Houivet  3 , Maud Maho-Vaillant  1   2 , Marie-Laure Golinski  1   2 , Sébastien Calbo  2 , Catherine Prost-Squarcioni  4 , Bruno Labeille  5 , Catherine Picard-Dahan  6 , Guillaume Chaby  7 , Marie-Aleth Richard  8 , Emmanuelle Tancrède-Bohin  9 , Sophie Duvert-Lehembre  10   11 , Emmanuel Delaporte  12 , Philippe Bernard  13 , Frédéric Caux  4 , Marina Alexandre  4 , Philippe Musette  4 , Saskia Ingen-Housz-Oro  14 , Pierre Vabres  15 , Gaëlle Quereux  16 , Alain Dupuy  17 , Sébastien Debarbieux  18 , Martine Avenel-Audran  19 , Michel D'Incan  20 , Christophe Bédane  21 , Nathalie Bénéton  22 , Denis Jullien  23 , Nicolas Dupin  24 , Laurent Misery  25 , Laurent Machet  26 , Marie Beylot-Barry  27 , Olivier Dereure  28 , Bruno Sassolas  29 , Nadège Cordel  30 , Géraldine Jeudy  31 , Jacques Benichou  32 , Vivien Hébert  1   2 , Pascal Joly  1   2
Affiliations

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris

Billal Tedbirt et al. JAMA Dermatol. .
No abstract available

Plain language summary

This cohort study examines the safety and efficacy of rituximab for patients with pempigus foliaceus.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Caux reported being an investigator for Argenx, Principia Biopharma, and Regeneron and personal fees from Sanofi outside the submitted work. Dr Joly reported consulting fees from Amgen, Argenx, Astra Zeneca, Thermofisher, Sanofi, Akari, Janssen, Novartis, Servier, Chugai, Kezar Life Science, Regeneron, UCB, Principabio, Zenyaku Kogyo, Dualyx, Amgen, JJP Biologics. Dr Barry reported personal fees from Janssen, Lilly, Novartis, Amgen, and AbbVie. Dr Jullien reported personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, Leo, Lilly, MSD, MEDAC, Novartis, Pfizer, UCB, and Sanofi. Dr Caux reported personal fees from Argenx, Regeneron, Kezar Life Sciences, Sanofi, and Leo Pharma. Dr Nupin reported personal fees from BMS, Novartis, Almirall, UCB, and Viatris. No other disclosures were reported.

References

    1. Almugairen N, Hospital V, Bedane C, et al. . Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. 2013;69(4):583-588. doi:10.1016/j.jaad.2013.05.016 - DOI - PubMed
    1. Jelti L, Cordel N, Gillibert A, et al. ; French Study Group on Autoimmune Blistering Diseases . Incidence and mortality of pemphigus in France. J Invest Dermatol. 2019;139(2):469-473. doi:10.1016/j.jid.2018.07.042 - DOI - PubMed
    1. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. ; French Study Group on Autoimmune Bullous Skin Diseases . First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040. doi:10.1016/S0140-6736(17)30070-3 - DOI - PubMed
    1. Joly P, Mouquet H, Roujeau JC, et al. . A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-552. doi:10.1056/NEJMoa067752 - DOI - PubMed
    1. Vivien H, Hamwi S, Tancrède-Bohin E, et al. . Optimizing pemphigus management with rituximab and short-term relapse predictors. JAMA Dermatol. Published online February 5, 2025. doi:10.1001/jamadermatol.2024.6130 - DOI - PMC - PubMed

LinkOut - more resources